Brentuximab Vedotin

證據等級: L5

預測適應症: 10 個

Brentuximab Vedotin: From Hodgkin Lymphoma to Follicular Lymphoma

One-Sentence Summary

Brentuximab vedotin (BV) is a CD30-targeting antibody-drug conjugate approved globally for relapsed/refractory classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL), though it currently holds no Taiwan regulatory authorization. The TxGNN model predicts it may be effective for follicular lymphoma, with 6 clinical trials and 20 publications currently supporting this direction, including one actively recruiting Phase 2 trial.

Quick Overview

Item	Content
Original Indication	Hodgkin lymphoma / systemic anaplastic large cell lymphoma (globally approved; not registered in Taiwan)
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.89%
Evidence Level	L2
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Brentuximab vedotin is an antibody-drug conjugate (ADC) composed of an anti-CD30 monoclonal antibody (brentuximab) covalently linked to the potent cytotoxin monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon binding to CD30-expressing tumor cells, the conjugate is internalized, MMAE is released intracellularly, and microtubule polymerization is disrupted — inducing G2/M cell cycle arrest and apoptosis. This targeted delivery mechanism is the cornerstone of BV’s utility across CD30-expressing malignancies.

Follicular lymphoma (FL) is a low-grade B-cell non-Hodgkin lymphoma that does not uniformly express CD30. However, CD30 expression is detectable in a clinically relevant subset — particularly in cases with higher tumor burden or during histological transformation to diffuse large B-cell lymphoma (DLBCL) or anaplastic large cell lymphoma (ALCL), where CD30 upregulation is well-documented. A case report (PMID 32476657) directly demonstrates BV achieving complete response in a Grade I FL that transformed to CD30+ ALK1− ALCL, illustrating this mechanistic pathway in real patients.

The prediction therefore carries a biologically grounded rationale, provided patient selection relies on prospective CD30 immunohistochemistry (IHC) screening. One ongoing Phase 2 trial (NCT04587687) is directly investigating BV plus bendamustine in relapsed/refractory FL, representing the most immediate clinical test of this hypothesis.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04587687	Phase 2	Recruiting	23	BV + bendamustine for R/R follicular lymphoma; currently enrolling; provides the most direct clinical evidence for this repurposing direction
NCT02594163	Phase 2	Terminated	25	Randomized trial of rituximab + bendamustine ± BV for R/R CD30+ DLBCL; terminated early but 25 patients enrolled provide partial efficacy signals applicable to the FL/DLBCL spectrum
NCT01805037	Phase 1/2	Terminated	20	BV + rituximab as frontline for CD30+ and/or EBV+ lymphomas (FL eligible); terminated with 20 patients, providing preliminary safety data in a CD30-selected lymphoma population
NCT02623920	Phase 2	Withdrawn	0	Planned BV + bendamustine + rituximab for R/R CD30+ B-cell NHL including FL; withdrawn before enrollment — study design directly relevant but no efficacy data obtained
NCT04138875	Phase 2	Withdrawn	0	Risk-stratified sequential rituximab + BV ± bendamustine for newly diagnosed CD20/CD30+ post-transplant lymphoproliferative disorder; withdrawn before enrollment
NCT04795869	Phase 2	Withdrawn	0	BV + pembrolizumab for recurrent PTCL; withdrawn — indirect relevance; suggests checkpoint inhibitor combinations merit consideration

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40758949	2025	Phase 2 Study	Blood Advances	LYSA Phase 2 study of BV + gemcitabine (GBV) followed by BV maintenance in R/R PTCL; ORR evaluated after 4 induction cycles in CD30+ (≥5%) patients
32476657	2020	Case Report	Gulf J Oncology	Grade I FL transforming to CD30+ ALK1− ALCL — complete response achieved with BV + high-dose methotrexate; direct clinical demonstration of BV efficacy in FL transformation
34797505	2022	Prospective Clinical Study	Advances in Therapy	Real-world study of BV + CEP in untreated CD30+ PTCL (including TFH phenotype); high overall remission rates in CD30+ B/T-cell lymphomas
33320379	2021	Retrospective Cohort	Eur J Haematol	BV + ICE (ifosfamide, carboplatin, etoposide) for R/R PTCL; assessed BV combination efficacy in relapsed lymphoma with poor prognosis
39644004	2024	Review	Hematology (ASH Ed.)	Comprehensive review of BV and novel agents in PTCL management, including frontline and salvage settings
38306597	2024	Review	Blood	Treatment of common nodal PTCL subtypes; documents BV + CHP as established frontline regimen for CD30+ disease
35663281	2022	Review	Leukemia Research Reports	Immunotherapy in indolent NHL including FL; reviews emerging roles of novel agents in FL treatment landscape
41409526	2025	Case Report	Skin Appendage Disorders	Extensive alopecia mucinosa (folliculotropic mycosis fungoides) responding to BV; demonstrates activity in follicle-associated T-cell malignancy
28340875	2017	Review	Hematol Oncol Clin N Am	Angioimmunoblastic T-cell lymphoma (T-follicular helper-derived); BV discussed as novel therapeutic approach
28967896	2018	Review	Bone Marrow Transplantation	Post-ASCT maintenance in lymphomas including FL; BV referenced in maintenance framework applicable to FL

Taiwan Regulatory Information

Brentuximab vedotin is currently not registered or marketed in Taiwan. No Taiwan FDA (TFDA) product licenses have been issued.

Internationally, brentuximab vedotin (Adcetris®) has received regulatory approval in the United States (FDA), European Union (EMA), Japan (PMDA), and other jurisdictions for relapsed/refractory classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Any clinical use in Taiwan for follicular lymphoma would require either a new TFDA approval application or an expanded access / compassionate use protocol.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — Antibody-Drug Conjugate (ADC); anti-CD30 antibody conjugated to MMAE (microtubule-disrupting cytotoxin; conventional cytotoxic payload)
Myelosuppression Risk	High — neutropenia is the most frequently reported serious adverse event; febrile neutropenia occurs; G-CSF prophylaxis is commonly employed
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential (prior to each cycle), peripheral neuropathy assessment (clinical grading each visit), liver function tests, renal function
Handling Protection	Must follow cytotoxic drug handling regulations; MMAE is a potent antimitotic agent — standard ADC/cytotoxic handling precautions apply

Safety Considerations

No Taiwan TFDA contraindication or warning data is available (TFDA SmPC not retrieved — classified as a blocking data gap per DG001). Based on published clinical literature, the following safety signals are established for brentuximab vedotin:

Peripheral neuropathy: Cumulative, dose-limiting toxicity — both sensory and motor neuropathy are well-documented across trials; dose delays and reductions are frequently required
Severe neutropenia / febrile neutropenia: The most common hematological toxicity; prophylactic G-CSF is recommended in many protocols
Progressive multifocal leukoencephalopathy (PML): Rare but potentially fatal JC virus reactivation has been reported; requires vigilance especially in immunocompromised patients
Pulmonary toxicity: Non-infectious pneumonitis has been reported and may be treatment-limiting

Please retrieve the full TFDA SmPC or reference the EMA/FDA prescribing information for complete contraindications and drug interaction data before clinical application.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic link between BV and follicular lymphoma is biologically plausible via CD30 expression in a subset of FL patients (especially at transformation), and an actively recruiting Phase 2 trial (NCT04587687) provides direct prospective evidence generation. Evidence at L2 is sufficient to support continued development, but patient selection by CD30 IHC is essential and efficacy data from the ongoing trial remains awaited.

To proceed, the following is needed:

Results from NCT04587687: This actively recruiting Phase 2 trial of BV + bendamustine in R/R FL is the critical evidence gate — monitor for interim and final readouts
CD30 IHC prevalence data in FL: Characterize the proportion of FL patients with clinically meaningful CD30 expression (commonly defined as ≥10% or ≥1% by IHC) to estimate the eligible patient population in Taiwan
Taiwan TFDA approval or expanded access pathway: BV is not registered in Taiwan; a regulatory strategy (new NDA or compassionate use) must be defined before any clinical application
Complete safety profile retrieval: Download TFDA SmPC PDF (or EMA/FDA label) to address data gap DG001 (blocking) and enable full safety assessment
MOA confirmation via DrugBank API: Address data gap DG002 (high severity) to support formal mechanistic rationale documentation
Dose and schedule optimization for FL: Confirm whether standard BV dosing (1.8 mg/kg IV Q3W) is appropriate, or whether the weekly schedule (1.2 mg/kg QW) used in some ADC trials offers a better tolerability profile for indolent FL patients
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.